About Us
Theranovir team brings expertises in drug development with scientific, clinical, financial and industry background.
Operational Team
Zakia BELAID-SANDAL (PhD)
HEC-Challenge+
Chief Executive Officer, Founder
17 years of experience in leading and participating in oncology programs in France and abroad
4 co-invented patents
Giorgio Massimini (PhD, MD)
Chief Medical Officer
Former VP Early Clinical Oncology at MerckGroup; over 40 years of experience in pharma. Previous clinical responsible for the development of Aromasin; Sutent, Tepmekoet others oncology drugs consultant for biotech companies.
Alexandre FONTAYNE (PhD)
Chief CMC Officer
Former President of Biothelis, SAS. President and expert of B4S consulting; Involved in ublituximab, roledumab and murlentamab development
Adyl CHAHET
Chief Financial Officer
President of Financyal, outsourced CFO, helps companies optimize financial strategy, performance, and growth. Ex-Deloitte M&A and Bpifrance private equity, expert in financial analysis, valuation, and deal structuring. Holds a Master’s in Financial Engineering (Paris 1 Panthéon-Sorbonne) and studied banking & finance in Switzerland.
Medical and Scientific Advisory Board
Zakia BELAID-SANDAL (Phd)
HEC-Challenge+
17 years of experience in leading and participating in oncology programs in France and abroad 4 co-invented patents
Alexandre Fontayne (PhD)
Former President of Biothelis, SAS. President and expert of B4S consulting; Involved in ublituximab, roledumab and murlentamab development
Radhia M’KACHER (PhD)
DNA Repair and Damage
CEO of Cell Environment
William KOHLBRENNER (PhD)
Formerly: AbbVie (Research/BD); VP Drug Development (BioLoomics); CSO (Life Science Nation). Currently advisor to several biotech companies.
Alexander EGGERMONT (MD, PhD)
​KOL for immuno-onco therapies, experience in leading European cancer institutions.
Azzedine BOUDJADJA (MD)
Oncology and Infectious diseases area
Former Medical Director at Bayer-Healthcare
Hervé FRIDMAN (MD, PhD)
Deputy Director of CARPEM and KOL for anti-cancer immuno-oncology
Christophe de ROMEUF (PhD)
Expert in monoclonal antibody preclinical studies, data room and team management.
Bords of directors
Zakia BELAID-SANDAL (PhD)
HEC-Challenge+
Chief Executive Officer, Founder, Board Member
17 years of experience in leading and participating in oncology programs in France and abroad 4 co-invented patents
Alexander EGGERMONT (MD, PhD)
Non executive director , Board Member
​KOL for immuno-onco therapies, experience in leading European cancer institutions.
Gilles COTTIER (PhD)
Non executive director , Board Member
Former CEO of Actylis; Former Executive VP Sigma-Aldrich; Broad industry domain expertise; Serves as an advisor to multiple companies